Last reviewed · How we verify
NCT03453918: POLYFER
Effects of Polyphenols on Iron Absorption in Iron Overload Disorders.
NA trial testing polyphenols in Dysmetabolic Iron Overload Syndrome in 41 participants. Completed in 20 July 2018.
20 July 2018
Quick facts
| Lead sponsor | University Hospital, Clermont-Ferrand |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | quadruple |
| Primary purpose | prevention |
| Enrollment | 41 |
| Start date | 9 April 2018 |
| Primary completion | 20 July 2018 |
| Estimated completion | 20 July 2018 |
| Sites | 1 location across France |
Drugs / interventions tested
- polyphenols
- Placebo
Conditions studied
- Dysmetabolic Iron Overload Syndrome — all drugs for Dysmetabolic Iron Overload Syndrome →
- Genetic Hemochromatosis — all drugs for Genetic Hemochromatosis →
- Iron Absorption — all drugs for Iron Absorption →
- Polyphenols — all drugs for Polyphenols →
Sponsor
University Hospital, Clermont-Ferrand
Who can join
18 and older, any sex, with Dysmetabolic Iron Overload Syndrome or Genetic Hemochromatosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Dysmetabolic iron overload syndrome and genetic hemochromatosis are frequent causes of iron overload. Polyphenols are efficient iron-chelators. Investigator hypothesize that polyphenol supplementation can reduce iron absorption in iron overload disease. Iron absorption can be studied by the area-under-the-curve of serum iron after iron oral loading. The primary outcome is the decrease of post-prandial serum iron after rich-iron meal, due to polyphenol supplementation.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effect of procyanidin on dietary iron absorption in hereditary hemochromatosis and in dysmetabolic iron overload syndrome: A crossover double-blind randomized controlled trial.
Lobbes H, Gladine C, Mazur A, Pereira B, et al · · 2020 · cited 7× · PMID 30792142 · DOI 10.1016/j.clnu.2019.02.012
Verify or expand the search:
- PubMed search for NCT03453918
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University Hospital, Clermont-Ferrand trials
Trials by the same sponsor.
- NCT07179276 — Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock · NA · recruiting
- NCT07476768 — PAINDYS_Characterizing Pain in Fibrous Dysplasia of Bone/McCune-Albright Syndrome: an Exploratory Pilot Study · NA · not yet recruiting
- NCT07439146 — Risk of Pneumonia in Intubated Patients in Emergency Situations · not yet recruiting
- NCT07427537 — Exploration of Circulating microRNAs as Biomarkers of Chemo-induced Peripheral Neuropathy: a Study in Cancer Patients · NA · recruiting
- NCT07330856 — Evaluation of Treatments for Dry or Productive Cough · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03453918 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Clermont-Ferrand
- Last refreshed: 1 April 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03453918.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing